Gan & Lee Pharmaceuticals Co Ltd (stock code: 603087.SH), a global biopharmaceutical company, announced on Wednesday that it has received orphan drug status from the European Medicines Agency (EMA) for the investigational drug GLR2007 intended to treat gliomas neuroepithelial tumours that originate from glial cells in the central nervous system.
The company's present clinical development program for GLR2007, a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, is exploring the treatment of advanced solid tumours that has the potential to offer treatment options for clinicians and patients.
The product has received Orphan drug status in the European Union based on a positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products.
Privo Technologies reports progress in oral cancer trial
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application